Literature DB >> 7598301

The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern.

C Salvarani1, S E Gabriel, W M O'Fallon, G G Hunder.   

Abstract

OBJECTIVE: To investigate trends in the incidence of giant cell arteritis over a 42-year period in Olmsted County, Minnesota.
DESIGN: Population-based incidence study.
SETTING: Olmsted County, Minnesota.
METHODS: All incidence cases of giant cell arteritis first diagnosed between 1950 and 1991 were identified using the unified record system at Mayo Clinic. Age- and sex-specific incidence rates were calculated using the number of incidence cases as the numerator and population estimates as the denominator. Overall rates were age- and sex-adjusted to the 1980 United States white population. The annual incidence rates were graphically illustrated using a 3-year centered moving average.
RESULTS: Between 1950 and 1991, 125 Olmsted County residents (103 women and 22 men) were diagnosed with giant cell arteritis. The age- and sex-adjusted incidence per 100,000 persons 50 years of age or older was 17.8 (95% CI, 14.7 to 21.0); incidence was significantly higher in women (24.2 [CI, 19.5 to 28.9]) than in men (8.2 [CI, 4.8 to 11.6]). Age-specific incidence rates increased with age (P < 0.0001). The annual incidence rates increased significantly over the study period (P = 0.002) and appear to have clustered in five peak periods, which occurred about every 7 years. A significant calendar-time effect was identified; it predicted an increase in incidence of 2.6% (CI, 0.9% to 4.3%) every 5 years.
CONCLUSIONS: Our observation of a regular cyclic pattern in incidence rates over time supports the hypothesis of an infectious cause for giant cell arteritis. Similar studies in other populations are needed to confirm our findings.

Entities:  

Mesh:

Year:  1995        PMID: 7598301     DOI: 10.7326/0003-4819-123-3-199508010-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  55 in total

1.  Systemic vasculitis: epidemiology, classification and environmental factors.

Authors:  D G Scott; R A Watts
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 2.  Polymyalgia rheumatica/temporal arteritis: recent advances.

Authors:  Maria-Louise Barilla-LaBarca; Deborah J Lenschow; Richard D Brasington
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

3.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 4.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 5.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 6.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  Giant cell arteritis.

Authors:  Todd J Schwedt; David W Dodick; Richard J Caselli
Journal:  Curr Pain Headache Rep       Date:  2006-12

8.  No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods.

Authors:  Florence Njau; Thomas Ness; Ulrike Wittkop; Thorsten Pancratz; Meike Eickhoff; Alan P Hudson; Hermann Haller; Annette D Wagner
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

Review 9.  Giant cell arteritis.

Authors:  Xiang Wang; Zhi Ping Hu; Wei Lu; Xiang Q Tang; He P Yang; Liu W Zeng; Jie Zhang; Ting Li
Journal:  Rheumatol Int       Date:  2008-08-21       Impact factor: 2.631

10.  Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise.

Authors:  Sibel Z Aydin; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.